Natera, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NTRA research report →
Range $245 – $500
Price Chart
About the company
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies.
- CEO
- Solomon Moshkevich
- IPO
- 2015
- Employees
- 6,138
- HQ
- Austin, TX, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a long-term uptrend, holding above its 200-day average at 271.37, but it has pulled back sharply from the 52-week high of 437.41. That keeps the regime constructive over the multi-month horizon, though momentum has cooled after a strong advance.
Street sentiment stays firmly positive, with a Buy consensus and an average target of 393.16 versus the current share price. Recent action has been mostly target raises and fresh Buy calls, even as one firm kept an Overweight rating unchanged after the CEO-transition pullback.
The earnings profile remains uneven: Natera has beaten EPS in only 2 of the last 8 quarters, and the latest print missed by a wide margin at -0.39 versus -0.17 expected. Analysts still see losses narrowing, with next-year EPS estimated at -0.3467, so execution and margin progress matter most.
Recent insider activity leans clearly negative, driven by 15 open-market sales and no buys. The repeated selling by co-founder/director Sheena Jonathan stands out as the main signal; there is no offsetting purchase pattern to balance it.
Profitability is still negative, but the operating profile is improving. Gross margin is 65.1%, revenue growth is 34.1% year over year, and free cash flow reached 321.5 million on 215.3 million of operating cash flow. The balance sheet is strong with 1.076 billion in cash and 861.8 million in net cash.
Natera screens as a premium diagnostics name, with a market cap of 41.8 billion and a valuation that remains rich versus the broader healthcare group. The setup favors a growth premium if execution holds, but the stock is priced for continued revenue expansion and margin leverage.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.64B
- P/E
- -252.17
- Fwd P/E
- 258.70
- PEG
- -3.68
- P/S
- 14.33
- P/B
- 22.15
- EV/EBITDA
- -292.76
- Div Yield
- 0.00%
- Gross Margin
- 65.21%
- Op Margin
- -8.95%
- Net Margin
- -5.66%
- ROE
- -9.18%
- ROIC
- -8.54%
Latest fiscal year · YoY change
- Revenue
- $2.31B+35.9%
- Gross Profit
- $1.50B+46.2%
- Op Income
- $-309,911,000
- Net Income
- $-208,160,000-9.3%
- EPS
- $-1.52+0.7%
- OCF Growth
- +58.7%
- FCF Growth
- +57.6%
- 52W High
- $437.41
- 52W Low
- $181.00
- 50D MA
- $376.63
- 200D MA
- $272.66
- Beta
- 1.51
- RSI (14)
- 26
- Avg Volume
- 1.77M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Natera delivered a strong Q3 with 34% reported revenue growth, 65% gross margin, accelerating Signatera volumes, and a raised full-year revenue outlook above $3 billion, while announcing Steven Chapman’s planned CEO transition to Solomon Moshkevich.· November 5, 2026
- Processed about 1.1 million tests in Q3, up more than 22% from about 894 thousand a year ago.
- Reported revenue was $794 million, up about 34% year over year; excluding true-ups, revenue grew more than 40%.
- Gross margin was about 65%; excluding true-ups, gross margin was 63.2%, up about 140 basis points sequentially.
- Clinical MRD units reached about 316 thousand, up 56% year over year and about 33 thousand sequentially.
- Management raised full-year 2026 revenue guidance to $3.05 billion-$3.35 billion and said 2027 should be another growth year.
Natera reported Q3 2026 revenue of $794 million, up about 34% from $592 million in Q3 2025; excluding true-ups, revenue grew more than 40% year over year. Gross margin was approximately 65%, while gross margin excluding true-ups was 63.2%, up about 140 basis points sequentially. Clinical MRD units were about 316 thousand, up 56% year over year, and total tests processed were about 1.1 million, up more than 22% from about 894 thousand. Management raised full-year 2026 revenue guidance to $3.05 billion-$3.35 billion from $2.85 billion-$2.91 billion, kept gross margin guidance at 64%-66%, increased the top end of R&D by $25 million, and raised the top end of SG&A to $1.3 billion. For 2027, management said OpEx growth should be in the 10% to 12% range.
Steven Chapman said the CEO transition was timed from a position of strength and framed Solomon Moshkevich as the right successor given his long history with the company and leadership in oncology. Solomon said there would be no radical strategic shift and that Natera would stick to the formula of strong customer service, practice-changing data, and best-in-class products. He also emphasized a long-term ambition to double revenue to $6 billion by 2029, with only minimal contribution expected from the emerging cancer screening business.
Michael Brophy focused on underlying financial leverage and the investment cadence. He said true-ups came down meaningfully, helping revenue and margin clarity, and noted that losses narrowed substantially year over year even as the company kept investing. He guided 2026 gross margin to 64%-66%, explained the higher R&D and SG&A ranges as driven by pharma/data expansion, clinical trial timing, FIND costs, and some legal spend, and said 2027 OpEx growth should be 10% to 12% as the company keeps investing while remaining cash-flow generative.
Analysts pressed on the $6 billion 2029 target, and management said it does not require “miracles,” with Solomon indicating Signatera could get there without getting much beyond $14.50 ASP and with growth driven mainly by existing businesses, international expansion, and pharma/data licensing. They also asked about the CEO transition; management said the board and Steven agreed the timing was right because the company is already in a strong position. On HCC and other MolDx submissions, management said the new coverage is encouraging, 9-10 additional submissions are in flight, and these could support both volume and ASP expansion. Questions on Japan, competition, and gross margins elicited confident but cautious answers: Japan is expected to be an important launch with potentially accretive pricing, competition is not viewed as a major change, and margins are expected to trend toward 70%+ over time despite near-term COGS pressure from newer products.
The call showed accelerating Signatera demand, with a second straight quarter of strong sequential MRD growth and broader adoption across tumor types. Management highlighted multiple catalysts ahead: Japan launch, additional MolDx decisions, pharma study momentum, and FIND study completion, while also saying the business can still grow materially without relying on early cancer screening.
The company is increasing OpEx to fund pharma, data, and clinical trial initiatives, and some of that spending is tied to programs that do not yet generate revenue. Management also acknowledged near-term COGS pressure from newer products like Signatera Genome and Fetal Focus, plus uncertainty around the timing and order of reimbursement wins. The 2029 $6 billion target depends on sustained execution and assumes early cancer screening remains only a small contributor in that window.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.6%
- Shares Outstanding
- 145.00M
- Float Shares
- 135.69M
of shares held by institutions
888 13F filers
Buy/sell ratio 0.01. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for NTRA, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Josh GottheimerHouse · NJ05 | Buy | Sep 22, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Aug 22, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jul 22, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Nov 20, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Apr 10, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Mar 6, 23 | Filing → |
| William Francis HagertySenate · TN | Sell | Apr 20, 21 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Jpmorgan Chase & Co | 14.04M | ▲ 1.17M |
| Fmr LLC | 13.68M | ▲ 8.23M |
| Vanguard Group Inc | 12.31M | ▼ 82.61K |
| Blackrock, Inc. | 10.61M | ▼ 304.14K |
| Price T Rowe Associates Inc | 6.78M | ▼ 2.24M |
| Vanguard Capital Management LLC | 6.24M | ▲ 11.17K |
| Vanguard Portfolio Management LLC | 5.73M | ▼ 48.20K |
| State Street Corp | 3.69M | ▲ 30.11K |
| Duquesne Family Office LLC | 3.16M | ▼ 25.64K |
| Wellington Management Group Llp | 2.85M | ▼ 1.20M |
| Geode Capital Management, LLC | 2.69M | ▼ 55.56K |
| Franklin Templeton Inc | 2.60M | ▼ 123.02K |
Held by 1,434 ETFs
Biggest fund positions in NTRA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Sheena Jonathan | sell | 40 |
| Nov 11, 26 | Sheena Jonathan | sell | 40 |
| Nov 11, 26 | Sheena Jonathan | sell | 48 |
| Nov 11, 26 | Sheena Jonathan | sell | 85 |
| Nov 11, 26 | Sheena Jonathan | sell | 145 |
| Nov 11, 26 | Sheena Jonathan | sell | 182 |
| Nov 11, 26 | Sheena Jonathan | sell | 240 |
| Nov 11, 26 | Sheena Jonathan | sell | 240 |
| Nov 11, 26 | Sheena Jonathan | sell | 120 |
| Nov 11, 26 | Sheena Jonathan | sell | 160 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NTRA coverage
Recent articles, reports, and earnings notes.

Natera (NTRA): Growth Premium Faces Valuation Risk
Natera is delivering rapid revenue growth and record oncology volume, but its premium valuation leaves little room for execution missteps. The stock is a Hold as reimbursement gains and clinical adoption are balanced against ongoing GAAP losses.

Natera, Inc. (NTRA) falls 14.6% after Q3 earnings
Natera, Inc. (NTRA) falls sharply after its Q3 report as investors focus on a wider-than-expected loss, despite strong revenue growth and higher 2026 guidance. The selloff reflects an expectations reset, with a CEO transition and valuation pressure adding to the move.

Natera, Inc. (NTRA) slumps 15% after earnings miss
Natera, Inc. (NTRA) slumps after reporting strong revenue growth but a much larger-than-expected quarterly EPS loss. Investors are weighing rising spending, a CEO transition, and whether the company can turn rapid oncology test growth into better earnings.
Want a deeper read on NTRA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
2,453 Shares in Natera, Inc. $NTRA Acquired by Banco Santander S.A.
defenseworld.net · Nov 20
Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?
fool.com · Nov 19
Allspring Mid Cap Growth Fund Q3 2026 Contributors And Detractors
seekingalpha.com · Nov 19
Alger Capital Appreciation Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 18
Billionaire Stanley Druckenmiller Says He's 'Staying Away' From Stocks. Here's What He Bought and Sold Last Quarter
fool.com · Nov 17
HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
businesswire.com · Nov 17
Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”
defenseworld.net · Nov 17
Natera, Inc. $NTRA Stock Sold by Eurizon Capital SGR S.p.A.
defenseworld.net · Nov 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 17, 2026 · Live quote · Not investment advice